- FCPA Professor - https://fcpaprofessor.com -

The Largest FCPA Enforcement Actions Involving Healthcare Related Companies

In large part due to the expansive FCPA enforcement theory that physicians, lab personnel and others associated with most foreign healthcare systems are “foreign officials” under the FCPA (first brought to the FCPA context in 2002 – see here [1] for the prior post), healthcare related companies have resolved numerous FCPA enforcement actions.

This post highlights the twenty largest FCPA enforcement actions (as measured by settlement amount) involving healthcare related companies (broadly speaking pharmaceutical, medical device, life sciences, and diagnostic companies as well as those selling health related products).

As indicated by the below list, the top three enforcement actions involve foreign companies.

Company Amount               Year

 

1.      Teva Pharmaceutical $519 million

(DOJ – $283 million)

(SEC – $236 million)

2016
2.      Novartis $347 million

(DOJ – $234 million)

(SEC – $113 million)

2020
3.      Fresenius Medical Care $231.7 million

(DOJ – $84.7 million)

(SEC – $147 million)

2019
4.      Avon $135 million

(DOJ – $67.6 million)

(SEC – $67.4 million)

2014

 

5.      Johnson & Johnson $70 million

(DOJ – $21 million)

(SEC – $49 million)

2011
6.      Pfizer / Wyeth $60 million

(DOJ – $15 million)

(SEC – $45 million)

2012
7.      Stericycle $59 million

(DOJ – $35 million)

(SEC – $24 million)

2022
8.      Bio-Rad Laboratories $55 million

(DOJ – $14.5 million)

(SEC – $40.5 million)

2014
9.      Zimmer Biomet $30.4 million

(DOJ – $17.4 million)

(SEC – $13 million)

2017

 

10.      Eli Lilly $29.4 million

(SEC – $29.4 million)

2012
11.      Sanofi $25.2 million

(SEC – $25.2 million)

2018
12.      Novartis

 

$25 million

(SEC – $25 million)

2016
13.      Biomet $22.8 million

(DOJ – $17.3 million)

(SEC – $5.5 million)

2012
14.      Olympus Latin America $22.8 million

(DOJ – $22.8 million)

2016
15.      Smith & Nephew $22.2 million

(DOJ – $16.8 million)

(SEC – $5.4 million)

2012
16.     Alexion Pharmaceuticals 21.5 million

(SEC – 21.5 million)

2020
17.      GlaxoSmithKline $20 million

(SEC – $20 million)

2016

 

18.      Analogic  / BK Medical

 

$14.9 million

(DOJ – $3.4 million)

(SEC – $11.5 million)

2016
19.      Bristol-Myers $14.7 million

(SEC – $14.7 million)

2015

 

 

20.      Stryker $13.2 million

(SEC – $13.2 million)

2013

[2]